Safetyefficacy of an intravasal, one-time injectablenon-hormonal male contraceptive (RISUG): A clinical experience

Autor: Ajit Kumar Mathur, Radhey Shyam Sharma, Hem Chandra Das, Devinder Toor, Sujoy K. Guha, Gulshan Jeet Singh, Rajeev Singh
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
Volunteers
safety
medicine.medical_specialty
intravasal male contraceptive
Polyesters
030106 microbiology
efficacy
lcsh:Medicine
Male contraceptive
Semen
urologic and male genital diseases
sperm
General Biochemistry
Genetics and Molecular Biology
Injections
03 medical and health sciences
0302 clinical medicine
Vas Deferens
Pregnancy
Reversible inhibition of sperm under guidance
medicine
Azoospermia - efficacy - intravasal male contraceptive - RISUG - safety - sperm
Animals
Humans
030212 general & internal medicine
Adverse effect
Spouses
Azoospermia
Injection Procedure
business.industry
Obstetrics
lcsh:R
Contraceptive Agents
Male
General Medicine
medicine.disease
Spermatozoa
Clinical trial
Semen Analysis
RISUG
Contraception
Polystyrenes
Female
Original Article
business
Zdroj: The Indian Journal of Medical Research
Indian Journal of Medical Research, Vol 150, Iss 1, Pp 81-86 (2019)
ISSN: 0971-5916
Popis: Background & objectives: For improved male contraception, a new polymeric drug molecule – Reversible Inhibition of Sperm under Guidance (RISUG) has been synthesized and has been found to be effective, safe and reversible in various animal species. Phase-I and phase-II clinical trials have confirmed its safety and contraceptive efficacy. The present study was undertaken as a multicentric-limited phase-III clinical trial to test the efficacy and safety of RISUG in human volunteers. Methods: One hundred and thirty nine young males each having at least two children and living with wife were given 120 μl of RISUG as bilateral vas intraluminal injection. After the single-dose administration, the individuals were followed in respect of general health and semen parameters. Their wives were also followed particularly to determine onset of pregnancy. Results: During the six month follow up, the health of male volunteers and their wives was normal with no significant adverse effects. Temporary scrotal enlargement and mild scrotal and inguinal region pain were manifested in most individuals and resolved within one month without any routine activity impairment. In six individuals, there was injection procedure failure and azoospermia was not achieved. The other 133 individuals had either severe oligozoospermia or azoospermia at the first semen examination one month following RISUG injection; 82.7 per cent individuals had continued azoospermia in the month following first semen examination onwards and the rest 17.3 per cent manifested azoospermia within three to six months. Interpretation & conclusions: RISUG intravasal injection appears to be a safe clinical procedure with no significant adverse effects and has high sustained contraceptive efficacy. The localized intervention and continued contraceptive action on single-dose administration were significant features of the RISUG technology.
Databáze: OpenAIRE
Externí odkaz: